person · Reporting owner
Simms Christopher Paul
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | See Remarks | March 25, 2026 | March 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date March 25, 2026 · Filed March 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.88 · Expires 2036-03-24 | Direct | 219,000 |
Reported balance
After 2026-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-25 · Grant · Acquired 219,000 · Balance 219,000 F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IVERIC bio, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 1
1 source rowRow 1 · 2023-07-11 · Disposition to issuer · Disposed 32,429 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-11 · Disposition to issuer · Disposed 56,250 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-11 · Disposition to issuer · Disposed 18,750 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-11 · Disposition to issuer · Disposed 37,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2031-08-01 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-11 · Disposition to issuer · Disposed 160,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.83 · Expires 2031-12-16 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-11 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2032-12-19 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-07-11 · Disposition to issuer · Disposed 75,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2026 Filed Mar 27, 2026 16:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 219,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001193125-26-129154 · ownership.xml · derivative · entry 1 Simms Christopher Paul · CIK 0001877012 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,000 Underlying: Common Stock · 219,000 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 13:58 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $22.57 | Not disclosed |
DisclosureSEC source: 0001104659-23-080685 · tm2321002-6_4seq1.xml · derivative · entry 7 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2032-12-19 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 13:58 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $14.83 | Not disclosed |
DisclosureSEC source: 0001104659-23-080685 · tm2321002-6_4seq1.xml · derivative · entry 6 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2031-12-16 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 13:58 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerStock Option (Right to Buy) · Derivative | 160,000 | Not disclosed Strike: $8.64 | Not disclosed |
DisclosureSEC source: 0001104659-23-080685 · tm2321002-6_4seq1.xml · derivative · entry 5 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,000 shares Expires 2031-08-01 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 13:58 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerRestricted Stock Units · Derivative | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080685 · tm2321002-6_4seq1.xml · derivative · entry 4 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 13:58 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerRestricted Stock Units · Derivative | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080685 · tm2321002-6_4seq1.xml · derivative · entry 3 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 13:58 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerRestricted Stock Units · Derivative | 56,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080685 · tm2321002-6_4seq1.xml · derivative · entry 2 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,250 shares Expires not disclosed F2 · derivative.exercise_price: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 13:58 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Disposition to issuerCommon Stock | 32,429 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-080685 · tm2321002-6_4seq1.xml · nonDerivative · entry 1 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 18:33 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 2,368 | $20.06 | $47,502.08 |
DisclosureSEC source: 0001410939-23-000006 · wf-form4_167287517369662.xml · nonDerivative · entry 2 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,429 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on January 2, 2023. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $19.91 to $20.56 on January 3, 2023 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 18:33 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-23-000006 · wf-form4_167287517369662.xml · derivative · entry 3 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F4 · derivative.exercise_date: On December 16, 2021, the Reporting Person was granted 25,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. F4 · derivative.expiration_date: On December 16, 2021, the Reporting Person was granted 25,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 18:33 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-23-000006 · wf-form4_167287517369662.xml · nonDerivative · entry 1 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 18:54 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000146 · wf-form4_167175327919760.xml · derivative · entry 2 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027). Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 18:54 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $22.57 | $0.00 |
DisclosureSEC source: 0001410939-22-000146 · wf-form4_167175327919760.xml · derivative · entry 1 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 16:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 6,818 | $11.25 | $76,702.50 |
DisclosureSEC source: 0001410939-22-000092 · wf-form4_165964373903225.xml · nonDerivative · entry 4 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,547 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on August 2, 2022. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions ranging from $11.14 to $11.38 per share on August 3, 2022 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 16:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | SaleCommon Stock | 5,454 | $11.25 | $61,357.50 |
DisclosureSEC source: 0001410939-22-000092 · wf-form4_165964373903225.xml · nonDerivative · entry 3 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,365 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on August 2, 2022. F3 · price: The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions ranging from $11.14 to $11.38 per share on August 3, 2022 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 16:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000092 · wf-form4_165964373903225.xml · derivative · entry 6 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F6 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F6 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 16:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000092 · wf-form4_165964373903225.xml · derivative · entry 5 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F5 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 100% of the shares subject to the award on the first anniversary of the grant date. F5 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 100% of the shares subject to the award on the first anniversary of the grant date. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 16:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000092 · wf-form4_165964373903225.xml · nonDerivative · entry 2 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 16:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001410939-22-000092 · wf-form4_165964373903225.xml · nonDerivative · entry 1 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:34 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151726 · tm2135829-1_4seq1.xml · derivative · entry 2 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026). F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026). Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:34 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001104659-21-151726 · tm2135829-1_4seq1.xml · derivative · entry 1 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-16 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:02 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | PurchaseCommon Stock | 3,069 | $16.30 | $50,024.70 |
DisclosureSEC source: 0001104659-21-142468 · tm2132961-2_4seq1.xml · nonDerivative · entry 1 Simms Christopher Paul · CIK 0001877012 · SVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,069 Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 19:53 UTC | IVERIC bio, Inc. (ISEE) · Entity 111416 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-100270 · tm2124202-2_4seq1.xml · derivative · entry 3 Simms Christopher Paul · CIK 0001877012 · Senior Vice President, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F4 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 100% of the shares subject to the award on the first anniversary of the grant date. F4 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 100% of the shares subject to the award on the first anniversary of the grant date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 19:53 UTC | IVERIC bio, Inc. (ISEE) · Entity 111416 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-100270 · tm2124202-2_4seq1.xml · derivative · entry 2 Simms Christopher Paul · CIK 0001877012 · Senior Vice President, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock of the Registrant upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 19:53 UTC | IVERIC bio, Inc. (ISEE) · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $8.64 | $0.00 |
DisclosureSEC source: 0001104659-21-100270 · tm2124202-2_4seq1.xml · derivative · entry 1 Simms Christopher Paul · CIK 0001877012 · Senior Vice President, CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-08-01 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2019 Inducement Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.